Sherman Matthew L 4
4 · Deciphera Pharmaceuticals, Inc. · Filed Dec 14, 2023
Insider Transaction Report
Form 4
Sherman Matthew L
EVP & Chief Medical Officer
Transactions
- Award
Common Stock
2023-12-12+8,244→ 99,306 total - Sale
Common Stock
2023-12-13$15.37/sh−2,792$42,905→ 96,514 total
Footnotes (3)
- [F1]On February 15, 2023, the Reporting Person was granted restricted stock units ("RSUs"), which vest upon the satisfaction of three performance criteria. On December 12, 2023, the Issuer's Compensation Committee confirmed that performance criteria one had been met, resulting in the vesting of 8,244 RSUs.
- [F2]Includes 434 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on November 14, 2023.
- [F3]This sale was to cover tax liabilities in the vesting of RSUs.